Physician profile
Ryan T Foret
NPI 1770593485
$13,007.37
in general payments reported to CMS, 2019-2025
44 companies · $1,799 in 2025
The $1,799 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,043 · 2020: $1,821 · 2021: $1,962 · 2022: $1,948 · 2023: $1,816 · 2024: $1,618 · 2025: $1,799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,233.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,806.22 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,790.80 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,285.00 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $911.73 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $767.77 | 2019-2025 | Verquvo, Belsomra, Gardasil 9 |
| Amarin Pharma, INC. | $619.06 | 2019-2022 | |
| Esperion Therapeutics, INC. | $492.58 | 2020-2025 | Nexletol |
| Pfizer INC. | $467.37 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $379.43 | 2019-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $365.15 | 2019-2022 | |
| Allergan, INC. | $342.28 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $324.77 | 2019-2022 | |
| Amgen INC. | $322.05 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbott Laboratories | $320.44 | 2021-2025 | Freestyle Libre 3 |
| Supernus Pharmaceuticals, INC. | $308.40 | 2022-2025 | Qelbree, Qelbree |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Foret listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.